# A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

> **NCT04042441** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1122 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Degludec/Insulin Aspart

## Key facts

- **NCT ID:** NCT04042441
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-29
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 1122 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04042441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04042441, "A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04042441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*